Citations

Clear

1575 citation(s) found for "Im, Gene".

ZWC complex-mediated SPT5 phosphorylation suppresses divergent antisense RNA transcription at active gene promoters
Park, Kihyun , Jang, Jin Sung , Kim, Jihyun , Kim, Jihyun, Kim, Hye‐Jung , Lee, Jeong‐Heon , Kim, Jaehoon , Zhong, Jian , Lee, Jeong-Heon , Kim, Jihyun

Mayo Clinic

Nucleic Acids Research | March 13, 2022 | Volume: 50 | Issue: 7 | Pages: 3835-3851

10.1093/nar/gkac193 | PMID 35325203 Get It

Abstract The human genome encodes large numbers of non-coding RNAs, including divergent antisense transcripts at transcription start sites (TSSs). However, molecular mechanisms by which divergent antisense transcription is regulated have not been detailed. Here, we report a novel ZWC complex composed of ZC3H4, WDR82 and CK2 that suppresses divergent antisense transcription. The ZWC complex preferentially localizes at TSSs of active genes through direct interactions of ZC3H4 and WDR82 subunits with the S5p RNAPII C-terminal domain. ZC3H4 depletion leads to increased divergent antisense transcription, especially at genes that naturally produce divergent antisense transcripts. We further demonstrate that the ZWC complex phosphorylates the previously uncharacterized N-terminal acidic domain of SPT5, a subunit of the transcription-elongation factor DSIF, and that this phosphorylation is responsible for suppressing divergent antisense transcription. Our study provides evidence that the newly identified ZWC-DSIF axis regulates the direction of transcription during the transition from early to productive elongation.
Abstract P1-08-02: Cytochrome P450 reductase gene, POR, associated with paclitaxel induced peripheral neuropathy in patients of European ancestry from the adjuvant breast cancer trial, ECOG-ACRIN E5103
Xue, Gloria , Dang, Chau T. , Northfelt, Donald W. , Skaar, Todd, Schneider, Bryan P. , Shen, Fei , Jiang, Guanglong , Gardner, Laura , Philips, Santosh , Ly, Reynold C. , Osei, Wilberforce , Wu, Xi , Cantor, Erica , Miller, Kathy D. , Sledge, George W.

Mayo Clinic

Cancer Research | March 8, 2022 | Volume: 82 | Issue: 4_Supplement | Pages: P1-08-02-P1-08-02

10.1158/1538-7445.sabcs21-p1-08-02 Get It

Abstract Introduction: Paclitaxel induced peripheral neuropathy (TIPN) is one of the most important survivorship issues of cancer patients with the potential to substantially impact quality of life. TIPN can lead to dose reductions, early cessation, and has the potential to compromise treatment efficacy. We previously reported both rare (SBF2) and common germline (FCAMR) predictors for TIPN in patients of African descent through whole-exome sequencing (WES) and a genome-wide association study (GWAS), respectively, in the adjuvant, randomized phase III breast cancer trial, E5103. These predictors are now being evaluated in the prospective ECOG-ACRIN trial EAZ171 (NCT04001829). We have also previously reported our evaluation of common germline variants for patients of European descent through GWAS in E5103 with validation in another adjuvant breast cancer trial, E1199. Herein, we evaluated for rare variants that were associated with risk of TIPN in patients of European ancestry from WES in E5103. Methods: Gene-based rare variant analyses using SKAT were performed to compare select cases of severe TIPN (n=172) and controls without any evidence of TIPN (n=170) derived from E5103. Cases were defined as those with at least grade 3 TIPN and controls were optimally. matched by demographic and risk factors and had no reported evidence for TIPN of any grade. Germline WES was conducted using Ion Proton™ Sequencers from Life Technologies with an average >100X coverage of the exome. Rare variants with a minor allele frequency <3% predicted to be deleterious by protein prediction programs were retained for the analysis. 7,278 genes passed quality control and were included in the analysis, setting the threshold for significance at a p-value < 6.87 ×10-6 after Bonferroni correction. Results: Cytochrome P450 oxidoreductase (POR) was significantly associated with an increased risk of grade 3+ TIPN (p =1.82 ×10-6). Six variants predicted to be deleterious in POR were identified in the study population. Paclitaxel is predominately metabolized by cytochrome P450 (CYP) 2C8 and 3A4. A functional cytochrome P450 oxidoreductase is required for the catalytic activities of all 57 CYP family members to metabolize drugs, xenobiotics, and steroid hormones. Conclusion: Rare variants in cytochrome P450 oxidoreductase predicted an increased risk of severe TIPN in patients receiving paclitaxel. These rare variants in POR may modulate the catalytic activities of P450 enzymes that are responsible for paclitaxel metabolism and have a striking biological rationale as contributors to TIPN. Work is ongoing to validate these findings mechanistically and to identify strategies to nullify the impact of these deleterious variants. Citation Format: Fei Shen, Guanglong Jiang, Laura Gardner, Gloria Xue, Santosh Philips, Reynold Ly, Osei Wilberforce, Xi Wu, Erica Cantor, Chau Dang, Donald Northfelt, Todd Skaar, Kathy D. Miller, George Sledge, Bryan P Schneider. Cytochrome P450 reductase gene, POR, associated with paclitaxel induced peripheral neuropathy in patients of European ancestry from the adjuvant breast cancer trial, ECOG-ACRIN E5103 [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P1-08-02.
SMARCB1 and RB1 Gene: Novel Mutations in Neuroendocrine Tumors of Sinonasal Cavity
Chatzopoulos, Kyriakos , Wismayer, David J. Schembri, McKnight, Tory , Klug, Theodore , Barton, Blair M. , Bar‐Ad, Voichita , Johnson, Jennifer, Toskala, Elina , Rabinowitz, Mindy, Nyquist, Gurston , Chitguppi, Chandala , Gargano, Stacey , Choby, Garret , Low, Christopher M. , D’Souza, Glen , Parsel, Sean M. , Rosen, Marc R

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | March 4, 2022 | Volume: 83 | Issue: S 01 | Pages: S1-S270

10.1055/s-0042-1743931 Get It

Gene fusions in gastrointestinal tract cancers
Rahi, Hamed, Olave, Maria C. , Fritchie, Karen , Greipp, Patricia T. , Halling, Kevin C. , Kipp, Benjamin R. , Greipp, Patricia T , Graham, Rondell P.

Mayo Clinic

Genes, Chromosomes and Cancer | March 3, 2022 | Volume: 61 | Issue: 5 | Pages: 285-297

10.1002/gcc.23035 | PMID 35239225 Get It

AbstractFusion genes have been identified in a wide array of human neoplasms including hematologic and solid tumors, including gastrointestinal tract neoplasia. A fusion gene is the product of parts of two genes that are joined together following a deletion, translocation, or chromosomal inversion. Together with single nucleotide variants, insertions, deletions, and amplification, fusion genes represent one of the key genomic mechanisms for tumor development. Detecting fusions in the clinic is accomplished by a variety of techniques including break‐apart fluorescence in situ hybridization, reverse transcription‐polymerase chain reaction, and next‐generation sequencing. Some recurrent gene fusions have been successfully targeted by small molecule or monoclonal antibody therapies (ie targeted therapies), while others are used as biomarkers for diagnostic and prognostic purposes. The purpose of this review article is to discuss the clinical utility of detection of gene fusions in carcinomas and neoplasms arising primarily in the digestive system.
Gene expression in lung epithelial cells following interaction with Pneumocystis carinii and its specific life forms yields insights into host gene responses to infection
Kottom, Theodore J. , Carmona, Eva M. , Carmona, Eva M , Kottom, Theodore J , Limper, Andrew H.

Mayo Clinic

Microbiology and Immunology | March 1, 2022 | Volume: 66 | Issue: 5 | Pages: 238-251

10.1111/1348-0421.12972 | PMID 35229348 Get It

Abstract Pneumocystis spp. interacts with epithelial cells in the alveolar spaces of the lung. It is thought that the binding of Pneumocystis to host cell epithelium is needed for life cycle completion and proliferation. The effect of this interaction on lung epithelial cells has previously shown that the trophic form of this organism greatly inhibits p34 cdc2 activity, a serine/threonine kinase required for transition from the G 2 to M phase in the cell cycle. To gain further insight into the host response during Pneumocystis pneumonia infection, we used microarray technology to profile epithelial cell (A549) gene expression patterns following Pneumocystis carinii interaction. Furthermore, we isolated separate populations of cyst and trophic forms of P. carinii , which were then applied to the lung epithelial cells. Differential expression of genes involved in various cellular functions dependent on the specific P. carinii life form in contact with the A549 cell was identified. The reliability of our data was further confirmed by Northern blot analysis on a number of selected upregulated or downregulated transcripts. The transcriptional response to P. carinii was dominated by cytokines, apoptotic, and antiapoptosis‐related genes. These results reveal several previously unknown effects of P. carinii on the lung epithelial cell and provide insight into the complex interactions of host and pathogen.
Human outgrowth knee fibroblasts from patients undergoing total knee arthroplasty exhibit a unique gene expression profile and undergo myofibroblastogenesis upon TGFβ1 stimulation
Bayram, Banu , Thaler, Roman , Bettencourt, Jacob W. , Limberg, Afton K. , Sheehan, Kevin P., Owen, Aaron R. , Berry, Daniel J., Wijnen, André J. van , Dudakovic, Amel , Berry, Daniel J. , Sanchez-Sotelo, Joaquin, van Wijnen, Andre J , Abdel, Matthew P , Berry, Daniel J , Berry, Daniel J., Morrey, Mark E. , Sánchez‐Sotelo, Joaquín , Abdel, Matthew P.

Mayo Clinic

Journal of Cellular Biochemistry | February 28, 2022 | Volume: 123 | Issue: 5 | Pages: 878-892

10.1002/jcb.30230 | PMID 35224764 Get It

AbstractArthrofibrosis is characterized by excessive extracellular matrix (ECM) deposition that results in restricted joint motion after total knee arthroplasties (TKAs). Currently, treatment options are limited. Therefore, an in vitro model of knee‐related myofibroblastogenesis is valuable to facilitate investigation of the arthrofibrotic process, diagnostic and therapeutic options. In this study, we obtained intraoperative posterior capsule (PC), quadriceps tendon (QT), and suprapatellar pouch (SP) tissues from the knees of four patients undergoing primary TKAs for osteoarthritis. From these tissues, we isolated primary cells by the outgrowth method and subsequently characterized these cells in the absence and presence of the pro‐myofibroblastic cytokine, transforming growth factor beta 1 (TGFβ1). Light microscopy of knee outgrowth cells revealed spindle‐shaped cells, and immunofluorescence (IF) analysis demonstrated staining for the fibroblast‐specific markers TE‐7 and vimentin (VIM). These knee outgrowth fibroblasts differentiated readily into myofibroblasts as reflected by enhanced α‐smooth muscle actin (ACTA2) mRNA and protein expression and increased mRNA expression of collagen type 1 (COL1A1) and type 3 (COL3A1) with collagenous matrix deposition in the presence of TGFβ1. Outgrowth knee fibroblasts were more sensitive to TGFβ1‐mediated myofibroblastogenesis than adipose‐derived mesenchymal stromal/stem cells (MSCs). While outgrowth knee fibroblasts isolated from three anatomical regions in four patients exhibited similar gene expression, these cells are distinct from other fibroblastic cell types (i.e., Dupuytren's fibroblasts) as revealed by RNA‐sequencing. In conclusion, our study provides an in vitro myofibroblastic model of outgrowth knee fibroblasts derived from patients undergoing primary TKA that can be utilized to study myofibroblastogenesis and assess therapeutic strategies for arthrofibrosis.
Efficient healing of large osseous segmental defects using optimized chemically modified messenger RNA encoding BMP-2
Vega, Rodolfo E. De la , Griensven, Martijn van , Zhang, Wen , Coenen, Michael J., Nagelli, Christopher V. , Panos, Joseph A. , Silva, Carlos Julio Peniche , Geiger, Johannes , Plank, Christian , Evans, Christopher H. , Balmayor, Elizabeth R. , De La Vega, Rodolfo E , van Griensven, Martijn , Peniche Silva, Carlos J , Balmayor, Elizabeth R

Mayo Clinic

Science Advances | February 16, 2022 | Volume: 8 | Issue: 7 | Pages: No page available

10.1126/sciadv.abl6242 | PMID 35171668 Get It

Large segmental osseous defects heal poorly. Recombinant, human bone morphogenetic protein-2 (rhBMP-2) is used clinically to promote bone healing, but it is applied at very high doses that cause adverse side effects and raise costs while providing only incremental benefit. We describe a previously unexplored, alternative approach to bone regeneration using chemically modified messenger RNA (cmRNA). An optimized cmRNA encoding BMP-2 was delivered to critical-sized femoral osteotomies in rats. The cmRNA remained orthotopically localized and generated BMP locally for several days. Defects healed at doses ≥25 μg of BMP-2 cmRNA. By 4 weeks, all animals treated with 50 μg of BMP-2 cmRNA had bridged bone defects without forming the massive callus seen with rhBMP-2. Moreover, such defects recovered normal mechanical strength quicker and initiated bone remodeling faster. cmRNA regenerated bone via endochondral ossification, whereas rhBMP-2 drove intramembranous osteogenesis; cmRNA provides an innovative, safe, and highly translatable technology for bone healing.
ABCD‐GENE Score and Clinical Outcomes Following Percutaneous Coronary Intervention: Insights from the TAILOR‐PCI Trial
Angiolillo, Dominick J. , Lennon, Ryan J. , Goodman, Shaun G. , Kim, Sang‐Wook , O’Cochlain, Fearghas, So, Derek , Sweeney, John P., Rihal, Charanjit S. , Farkouh, Michael E. , Pereira, Naveen L. , Capodanno, Davide , Angiolillo, Dominick J , Lennon, Ryan J , Goodman, Shaun G , Kim, Sang-Wook , O'Cochlain, Fearghas, So, Derek Y , Sweeney, John , Rihal, Charanjit S. , Pereira, Naveen L

Mayo Clinic

Journal of the American Heart Association | February 8, 2022 | Volume: 11 | Issue: 4 | Pages: No page available

10.1161/jaha.121.024156 | PMID 35132875 Get It

Background In TAILOR‐PCI, genotype‐guided selection of P2Y 12 inhibitors after percutaneous coronary intervention did not significantly reduce the risk of ischemic events at 12 months. The Age, Body Mass Index, Chronic Kidney Disease, Diabetes, and Genotyping (ABCD‐GENE) score identifies patients with high platelet reactivity on clopidogrel at increased risk of ischemic events. The aim of this study was to investigate the value of the ABCD‐GENE score for tailoring P2Y 12 inhibitor selection after percutaneous coronary intervention. Methods and Results In a post hoc analysis of the TAILOR‐PCI, outcomes were analyzed by ABCD‐GENE score and allocation to genotype‐guided or conventional P2Y 12 inhibitor selection. Primary (death, myocardial infarction, or stroke) and secondary (cardiovascular death, myocardial infarction, stroke, stent thrombosis, or severe recurrent ischemia) outcomes were assessed. Among 3883 patients discharged on clopidogrel in the genotype‐guided and conventional therapy groups, 15.8% and 84.2% had high (≥10 points) or low (<10) ABCD‐GENE scores, respectively. At 12 months, both the primary (5.2% versus 2.6%, P <0.001) and secondary outcomes (7.7% versus 4.6%, P =0.001) were significantly increased in patients with high ABCD‐GENE score. Among 4714 patients allocated to genotype‐guided or conventional therapy, the former did not significantly reduce the 12‐month risk of the primary and secondary outcomes in both the high and low ABCD‐GENE score groups (p interaction =0.48 and 0.27, respectively). Conclusions Among patients with percutaneous coronary intervention on clopidogrel, the ABCD‐GENE score was helpful in identifying those at higher risk. The ABCD‐GENE score may potentially enhance the precision of tailored selection of P2Y 12 inhibitors, which needs to be confirmed in prospective investigations. Clinical Trial Registration URL: http://www.clinicaltrials.gov . Unique Identifier: NCT01742117.
Development and evaluation of safety and effectiveness of novel cancer screening tests for routine clinical use with applications to multicancer detection technologies
Doubeni, Chyke A. , Pennello, Gene , Carlson, Robert W. , Lau, Yan Kwan, Pennello, Gene A , Carlson, Robert W , Lau, Yan Kwan , Lin, Jennifer S , Doubeni, Chyke A.

Mayo Clinic

Cancer | February 8, 2022 | Volume: 128 | Issue: S4 | Pages: 883-891

10.1002/cncr.33954 | PMID 35133658 Get It

Multicancer screening is a promising approach to improving the detection of preclinical disease, but current technologies have limited ability to identify precursor or early stage lesions, and approaches for developing the evidentiary chain are unclear. Frameworks to enable development and evaluation from discovery through evidence of clinical effectiveness are discussed.
A Novel USP25::PDGFRA Gene Fusion in a 78 Year Old Patient with a Myeloid Neoplasm
Dalland, Joanna , Blackburn, Patrick R. , Reichard, Kaaren K. , Johnson, Sarah H. , Smadbeck, James B. , Vasmatzis, George , Hoppman, Nicole L., Xu, Xinjie, Greipp, Patricia T. , Peterson, Jess F. , Dalland, Joanna C , Peterson, Jess F , Greipp, Patricia T , Baughn, Linda B.

Mayo Clinic

Laboratory Medicine | January 27, 2022 | Volume: 53 | Issue: 5 | Pages: e134-e138

10.1093/labmed/lmac010 | PMID 35217871 Get It

Abstract The World Health Organization category of myeloid/lymphoid neoplasms with eosinophilia and PDGFRA rearrangements is composed of a heterogeneous group of neoplasms that can present as a myeloproliferative neoplasm, acute myeloid leukemia, myeloid sarcoma, or lymphoblastic leukemia/lymphoma. The overall outcome of these neoplasms is favorable with imatinib therapy. Herein, we describe an adult female patient with a myeloid neoplasm accompanied by eosinophilia and a novel USP25::PDGFRA gene fusion.